Lynparza extends progression-free survival in first-line advanced ovarian cancer, with or without BRCA mutations
pharmafile | August 14, 2019 | News story | Research and Development | AstraZeneca, Cancer, MSD, lynparza, ovarian cancer, pharma
New Phase 3 data has emerged on AstraZeneca and MSD’s Lynparza (olaparib), showing that the PARP inhibitor achieved its primary endpoint in the first-line maintenance of advanced ovarian cancer in patients with or without BRCA mutations when added to standard-of-care bevacizumab, compared to bevacizumab alone.
The companies declared that the drug combo was found to produce a £statistically-significant and clinically-meaningful improvement in progression-free survival (PFS)”, marking the second positive set of results for Lynparza in first-line ovarian cancer.
“The Phase 3 PAOLA-1 trial demonstrates MSD’s and AstraZeneca’s continued commitment to improving clinical outcomes for women with advanced ovarian cancer,” remarked Roy Baynes, Senior Vice President and Head of Global Clinical Development, Chief Medical Officer at MSD. “In this co-operative group trial sponsored by ARCAGY Research, maintenance treatment with Lynparza when added to a standard-of-care treatment was evaluated in an environment representative of real clinical practice. By studying Lynparza in this broader patient population, we have learned more about how it may help even more patients with advanced ovarian cancer in the future.”
José Baselga, Executive Vice President, Oncology R&D, added: “The positive results from the PAOLA-1 trial demonstrate a clear potential benefit of adding Lynparza to the standard-treatment bevacizumab for women with advanced ovarian cancer. Following positive results from the SOLO-1 trial for women with a BRCA gene mutation, the PAOLA-1 trial marks yet another positive Phase 3 trial for Lynparza as a first-line maintenance treatment for women with advanced ovarian cancer. We look forward to discussing the results with global health authorities as soon as possible.”
Both companies confirmed they would be presenting the full results of the trial at an upcoming medical meeting.
Matt Fellows
Related Content
Pharma sees climate disruption as growing supply-chain risk
Nine in ten pharmaceutical companies across the UK and G7 countries expect climate-related disruption to …
AI in pharma: From lab development to patient impact
In the decade to 2025, AI use in vaccine development has increased markedly but is …
Pharma&’s ovarian cancer therapy approved for use by NHS Scotland
Pharma& has announced that its treatment for ovarian cancer, Rubraca (rucaparib), has been accepted by …
